508 related articles for article (PubMed ID: 28605453)
1. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
[TBL] [Abstract][Full Text] [Related]
2. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
[TBL] [Abstract][Full Text] [Related]
3. Paraganglioma: not just an extra-adrenal pheochromocytoma.
Laird AM; Gauger PG; Doherty GM; Miller BS
Langenbecks Arch Surg; 2012 Feb; 397(2):247-53. PubMed ID: 22086065
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: A systematic review and meta-analysis.
Hamidi O; Young WF; Gruber L; Smestad J; Yan Q; Ponce OJ; Prokop L; Murad MH; Bancos I
Clin Endocrinol (Oxf); 2017 Nov; 87(5):440-450. PubMed ID: 28746746
[TBL] [Abstract][Full Text] [Related]
5. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
[TBL] [Abstract][Full Text] [Related]
6. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades.
Goffredo P; Sosa JA; Roman SA
J Surg Oncol; 2013 May; 107(6):659-64. PubMed ID: 23233320
[TBL] [Abstract][Full Text] [Related]
7. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
[TBL] [Abstract][Full Text] [Related]
8. Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma.
Dhir M; Li W; Hogg ME; Bartlett DL; Carty SE; McCoy KL; Challinor SM; Yip L
Ann Surg Oncol; 2017 Nov; 24(12):3624-3630. PubMed ID: 28884434
[TBL] [Abstract][Full Text] [Related]
9. Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series.
Strajina V; Dy BM; Farley DR; Richards ML; McKenzie TJ; Bible KC; Que FG; Nagorney DM; Young WF; Thompson GB
Ann Surg Oncol; 2017 Jun; 24(6):1546-1550. PubMed ID: 28058556
[TBL] [Abstract][Full Text] [Related]
10. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma.
Roman-Gonzalez A; Zhou S; Ayala-Ramirez M; Shen C; Waguespack SG; Habra MA; Karam JA; Perrier N; Wood CG; Jimenez C
Ann Surg; 2018 Jul; 268(1):172-178. PubMed ID: 28257320
[TBL] [Abstract][Full Text] [Related]
11. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma.
Ayala-Ramirez M; Palmer JL; Hofmann MC; de la Cruz M; Moon BS; Waguespack SG; Habra MA; Jimenez C
J Clin Endocrinol Metab; 2013 Apr; 98(4):1492-7. PubMed ID: 23436918
[TBL] [Abstract][Full Text] [Related]
12. Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma: A single institution experience.
Choi YM; Sung TY; Kim WG; Lee JJ; Ryu JS; Kim TY; Kim WB; Hong SJ; Song DE; Shong YK
J Surg Oncol; 2015 Dec; 112(8):815-21. PubMed ID: 26464058
[TBL] [Abstract][Full Text] [Related]
13. Pheochromocytoma and Paraganglioma Patients With Poor Survival Often Show Brown Adipose Tissue Activation.
Abdul Sater Z; Jha A; Hamimi A; Mandl A; Hartley IR; Gubbi S; Patel M; Gonzales M; Taïeb D; Civelek AC; Gharib AM; Auh S; O'Mara AE; Pacak K; Cypess AM
J Clin Endocrinol Metab; 2020 Apr; 105(4):1176-85. PubMed ID: 31903484
[TBL] [Abstract][Full Text] [Related]
14. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma.
Hescot S; Leboulleux S; Amar L; Vezzosi D; Borget I; Bournaud-Salinas C; de la Fouchardiere C; Libé R; Do Cao C; Niccoli P; Tabarin A; Raingeard I; Chougnet C; Giraud S; Gimenez-Roqueplo AP; Young J; Borson-Chazot F; Bertherat J; Wemeau JL; Bertagna X; Plouin PF; Schlumberger M; Baudin E;
J Clin Endocrinol Metab; 2013 Oct; 98(10):4006-12. PubMed ID: 23884775
[TBL] [Abstract][Full Text] [Related]
15. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma.
Kong G; Grozinsky-Glasberg S; Hofman MS; Callahan J; Meirovitz A; Maimon O; Pattison DA; Gross DJ; Hicks RJ
J Clin Endocrinol Metab; 2017 Sep; 102(9):3278-3287. PubMed ID: 28605448
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients With Malignant Pheochromocytoma and Paraganglioma.
Zheng L; Gu Y; Silang J; Wang J; Luo F; Zhang B; Li C; Wang F
Front Endocrinol (Lausanne); 2021; 12():684668. PubMed ID: 34234744
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of a large series of patients surgically treated for pheochromocytoma.
Khorram-Manesh A; Ahlman H; Nilsson O; Friberg P; Odén A; Stenström G; Hansson G; Stenquist O; Wängberg B; Tisell LE; Jansson S
J Intern Med; 2005 Jul; 258(1):55-66. PubMed ID: 15953133
[TBL] [Abstract][Full Text] [Related]
19. Local-Regional Recurrence of Pheochromocytoma/Paraganglioma: Characteristics, Risk Factors and Outcomes.
Cui Y; Ma X; Gao Y; Chang X; Chen S; Lu L; Tong A
Front Endocrinol (Lausanne); 2021; 12():762548. PubMed ID: 34899602
[TBL] [Abstract][Full Text] [Related]
20. Positive Impact of Genetic Test on the Management and Outcome of Patients With Paraganglioma and/or Pheochromocytoma.
Buffet A; Ben Aim L; Leboulleux S; Drui D; Vezzosi D; Libé R; Ajzenberg C; Bernardeschi D; Cariou B; Chabolle F; Chabre O; Darrouzet V; Delemer B; Desailloud R; Goichot B; Esvant A; Offredo L; Herman P; Laboureau S; Lefebvre H; Pierre P; Raingeard I; Reznik Y; Sadoul JL; Hadoux J; Tabarin A; Tauveron I; Zenaty D; Favier J; Bertherat J; Baudin E; Amar L; Gimenez-Roqueplo AP;
J Clin Endocrinol Metab; 2019 Apr; 104(4):1109-1118. PubMed ID: 30698717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
